MENINGOCOCCAL MENINGITIS VACCINE - PAGE française
Meningitis vaccines meet the requirements established by the World Health Organization and U.S. and European Pharmacopoeia. | Meningococcal meningitis A/C/Y/W-135/X Polysaccharide Vaccine
NmVac4-A/C/Y/W-135™ PATENT PENDING (Serotypes A,C,Y,W-135) for Adults and Children | Plain polysaccharide vaccine to protect from Meningococcal meningitis serogroups A/C/Y/W-135. (10/50-dose vials) for adults and children - 18-moths protective immunity | |
| Meningococcal meningitis A/C/Y/W-135/X - DT Conjugate Vaccine
NmVac4-A/C/Y/W-135 DT™ (Serotypes A,C,Y,W-135 Diphtheria toxoid conjugate) for infants and children < 5 PATENT PENDING | | Diphtheria conjugated polysaccharide vaccine to protect from Meningococcal meningitis serogroups A/C/Y/W-135 DT conjugate vaccine for infants, children and adults - 3 years protective immunity | | | |
| Meningococcal meningitis A+C Vaccine (Trading-in) (Serotypes A+C vaccine) for Adults and Children
ITS NOT A JN PRODUCT | | Plain polysaccharide vaccine to protect from Neisseria meningitis serogroups A and C (10-dose vials) call for volume discount and registration documents. | |
Our
other Trading products are:
Hepatitis B, Rabies and DPT vaccines
(Orders strictly accepted from Africa, South America, South East Asia, and Middle East) - not for sale in the United States. |